Discover the latest progress of OxTium Technology in AI bioscience.
Peking University Hospital and OxTium Technology have reached a strategic cooperation to jointly promote the GeneLLM™ large model to empower basic cancer research. Focusing on gastric cancer and colorectal cancer, integrating cfRNA and multi-omics data to improve early risk detection accuracy and accelerate medical translation.
Read moreOxTium Technology launches GeneLLM™, a large model that overcomes high computing costs, data complexity, and poor model generality in bioscience research. Its lightweight architecture with as few as 1.5B parameters significantly lowers the research barrier. As a scientific AI counterpart to DeepSeek, GeneLLM™ is deeply integrated into the Bioford™ platform, supporting multi-omics data integration. Through applications in cancer genomics and beyond, GeneLLM™ is leading the intelligent transformation of bioscience research.
Read moreOn November 29, OxTium Technology won the second prize in the "2024 New Generation AI (Shenzhen) Entrepreneurship and Innovation Competition" with its independently developed GeneLLM multi-omics large model and BioFord one-stop life science service platform. The judges highly praised its technological innovation and broad application. The technology promotes deep integration of AI and life sciences, empowering medical diagnosis, disease treatment, and biomanufacturing. OxTium will continue to drive efficient and precise solutions for the industry.
Read moreOxford PhD Jin Yongcheng leads an average age 31 team to found OxTium Technology, focusing on medical diagnostic large model GeneLLM, integrating AI and multi-omics data, winning national runner-up in entrepreneurship competition, partnering with MGI to advance medical AI innovation.
Read more